Fragment-Based Drug Discovery

Fragment-Based Drug Discovery (FBDD) is a methodology in pharmaceutical research that involves screening small, low-molecular-weight chemical fragments (typically <300 Da) against biological targets to identify starting points for drug development. These fragments bind weakly but specifically to target sites, and are then optimized through iterative design and synthesis into potent drug candidates. It contrasts with high-throughput screening by focusing on simpler molecules that offer better chemical tractability and coverage of chemical space.

Also known as: FBDD, Fragment-Based Lead Discovery, Fragment Screening, Fragment-Based Approach, Fragment-Based Design

Why learn Fragment-Based Drug Discovery?

Developers in computational chemistry, bioinformatics, or drug discovery should learn FBDD when working on early-stage drug design projects, as it efficiently identifies novel lead compounds with high ligand efficiency and reduced attrition rates. It is particularly useful for targeting 'undruggable' proteins or when traditional screening fails, enabling structure-based optimization using techniques like X-ray crystallography or NMR. This approach is critical in academia, biotech, and pharmaceutical industries for accelerating the discovery of therapeutics.

Learning Resources

• docs: Fragment-Based Drug Discovery: A Practical Introduction
• docs: Fragment-Based Drug Discovery: Lessons and Outlook
• course: Fragment-Based Drug Discovery - Online Course
• video: Introduction to Fragment-Based Drug Discovery (Video)
• book: Fragment-Based Drug Design: Methods and Protocols